An official website of the United States government
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting
Trial Status: active
This study will test an experimental drug called KQB198 in combination with imatinib. The
goal is to determine if this combination is safe and tolerable and assess how effective
the combination is at treating GIST. Imatinib has been approved by the FDA for the
treatment of different types of cancer including GIST.
Inclusion Criteria
Inclusion Criteria
All Participants:
- Unresectable or metastatic disease
- Tissue confirmation of GIST
- Valid results from local testing of blood or tumor tissue documenting the presence
of a KIT mutation (must not have exon 9 mutation) or PDGFRA mutation (must not have
PDGFRA D842V).
- Measurable disease per RECIST v1.1.
- Patients must be in 1st line of treatment for advanced or metastatic disease. Prior
imatinib is allowed in adjuvant or neoadjuvant setting, as long as imatinib was
stopped over 1 year ago.
- Adequate organ function and performance status
Exclusion Criteria
Participants are excluded from the study if any of the following criteria apply:
- Unable to swallow or GI condition that prevents absorption.
- Other active malignancies within the last 2 years.
- History of hypersensitivity to any component of KQB198 or imatinib.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07406633.
Locations matching your search criteria
United States
Michigan
Ann Arbor
University of Michigan Rogel Cancer Center
Status: Approved
Name Not Available
North Carolina
Chapel Hill
UNC Lineberger Comprehensive Cancer Center
Status: Approved
Name Not Available
Texas
Houston
M D Anderson Cancer Center
Status: Approved
Name Not Available
Washington
Seattle
Fred Hutch/University of Washington/Seattle Children's Cancer Consortium
